Silexion Therapeutics Corp. filed a Form 8-K on November 19, 2026, disclosing that a Nasdaq Hearings Panel granted the company continued listing on the Nasdaq Capital Market on November 18, 2026, subject to several time-bound conditions.

Key Highlights

  • Panel decision received: On November 18, 2026, Silexion received a favorable ruling from a Nasdaq Hearings Panel granting continued listing on the Nasdaq Capital Market, subject to conditions.
  • Shareholders' equity deadline: By December 4, 2026, the company must complete a planned private placement for net proceeds of $2.5 million and demonstrate compliance with Nasdaq's $2.5 million minimum shareholders' equity requirement.
  • Minimum bid price deadline: By November 24, 2026, the company must maintain a closing bid price of at least $1.00 per share for at least ten consecutive trading days.
  • Public offering requirement: By March 31, 2027, the company must complete a planned public offering of at least $5 million.
  • Compliance window: The company must maintain compliance with all Nasdaq listing requirements through May 15, 2027; failure to do so will result in immediate delisting.
  • Reverse split completed: The company effected a 1-for-24 reverse share split on November 10, 2026, effective for trading purposes on November 11, 2026, in furtherance of regaining compliance with the minimum bid price requirement.
  • No assurance provided: According to the filing, "There can be no assurance that the Company will satisfy the conditions imposed by the Panel or otherwise regain or maintain compliance with the applicable Nasdaq continued listing requirements."

Silexion Therapeutics: Nasdaq Hearing Outcome and Listing Conditions

According to the Form 8-K filed with the SEC on November 19, 2026, Silexion Therapeutics Corp. (NASDAQ:SLXN) disclosed that it received a favorable decision from a Nasdaq Hearings Panel on November 18, 2026. The ruling grants the company continued listing on the Nasdaq Capital Market following its appeal of a delisting determination issued by Nasdaq on August 18, 2026. The original delisting determination addressed two separate deficiencies: non-compliance with the $2.5 million minimum shareholders' equity requirement and non-compliance with the $1.00 minimum bid price requirement.

The Panel's decision, as described in the filing, imposes three specific conditions. First, by December 4, 2026, the company must complete a planned private placement for net proceeds of $2.5 million and demonstrate compliance with the minimum shareholders' equity requirement, including through a balance sheet dated no more than 60 days prior to the applicable regulatory filing. Second, by November 24, 2026, the company must demonstrate compliance with the minimum bid price requirement by maintaining a closing bid price of at least $1.00 per share for at least ten consecutive trading days. Third, by March 31, 2027, the company must complete a planned public offering of at least $5 million.

The filing also notes that in connection with efforts to regain compliance with the minimum bid price requirement, the company effected a 1-for-24 reverse share split on November 10, 2026, which became effective for trading on November 11, 2026. The filing contains forward-looking statements, which the company identifies as subject to risks and uncertainties, including the possibility that the company may not complete the required steps within the Panel's timeframes. The company notes it assumes no obligation to update those forward-looking statements.

What Was Disclosed

Silexion Therapeutics Corp. disclosed a Nasdaq Hearings Panel decision granting continued listing subject to conditions including a December 4, 2026 private placement deadline, a November 24, 2026 bid price compliance deadline, and a March 31, 2027 public offering requirement of at least $5 million.